Turning the Tide on Eosinophilic Granulomatosis With Polyangiitis

Target Audience

This activity is intended for pulmonology, clinical immunology/allergy, and rheumatology specialists as well as cardiology, nephrology, and gastroenterology clinicians who manage patients with eosinophilic granulomatosis with polyangiitis (EGPA).

Program Overview

EGPA, formerly known as Churg-Strauss syndrome, is a rare autoimmune small-vessel vasculitis that has a complex phenotype with symptomatology that affects multiple organ systems, including respiratory. Join us for this engaging Expert Roundtable to learn more about how your patients with asthma may have EGPA—and the newer, effective therapies that are now available to treat this disease. Multidisciplinary faculty will also review the pathophysiologic processes underlying EGPA development, best approaches for prompt diagnosis, and strategies for individualizing therapeutic regimens that improve patient outcomes. 

Educational Objectives

After completing this activity, the participant should be better able to:

1. Describe the epidemiology, multidimensional burdens, and pathophysiologic underpinnings of EGPA
2. Employ recommended diagnostic approaches for the prompt differential diagnosis of EGPA
3. Discuss the clinical profiles and trial data for current and emerging biologic therapies for EGPA
4. Construct therapeutic regimens for patients with EGPA to address underlying pathophysiologic processes, reduce corticosteroid exposure, and achieve and sustain remission

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score at least 70% on the posttest and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Michael E. Wechsler, MD, MMSc: Consulting Fees: Allakos, Amgen, Areteia Therapeutics, Arrowhead Pharmaceutical, AstraZeneca, Avalo Therapeutics, Belenos Bio, Celldex, Connect Biopharma, Eli Lilly, Equillium, Glaxosmithkline, Incyte, Jasper Therapeutics, Kinaset, Kymera, Merck, MyBiometry, Pharming, Phylaxis, Pulmatrix, Rapt Therapeutics, recludix Pharma, Roche/Genentech, Regeneron, Sanofi/Genzyme, Sentien, Sound Biologics, Tetherex Pharmaceuticals, Uniquity Bio, Upstream Bio, Verona Pharma, Zurabio; Stock Options: Upstream Bio

Praveen Akuthota, MD: Consulting Fees: Amgen, AstraZeneca, Connect Biopharma, Enveda, GlaxoSmithKline, Sanofi; Contracted Research: AstraZeneca, Sanofi

Anisha B. Dua, MD, MPH: Consulting Fees: Amgen, Abbvie, Astra Zeneca, Sanofi, GSK, Novartis; Contracted Research: Amgen Novartis

Jason M. Springer, MD: Consulting Fees: Acepodia, Clinical Trial Services, Neovii, NS Pharma, Zenas; Steering Committee: Neovii

The planners and managers have no relevant financial relationships with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.